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Abstract
Introduction: Middle ear glandular neoplasms are infrequent causes of a middle ear mass. They can
have exocrine and/or neuroendocrine differentiation. It is currently thought that these tumors are
indistinguishable each from another. Herein, we present a new case of a middle ear glandular
neoplasm. Our objective is to review all cases described in the literature in order to identify the
clinical features, the gross pathology, the histopathology, the immunohistochemistry, to discuss the
differential diagnosis, the treatment, the rate of recurrence, the follow-up, the incidence of
metastasis, the prognosis and to present a new classification of middle ear glandular neoplasm.
Case presentation
Methods: We performed a MEDLINE database search for MEA-related articles published between
1950 and March 2008. The information from the reports was analyzed.
Results: Ninety-four patients with a middle ear adenoma are included in this report. We uncovered
75 patients with a carcinoid tumor and 19 patients with a middle ear adenoma diagnosis; the most
common presenting symptom was a conductive hearing loss. Middle ear adenomas are lesions that
are typically white, gray or reddish brown. They are grossly vascular and well circumscribed, but not
encapsulated, and can entrap and destroy the ossicles. Histologically, the cuboidal to low columnar
cells are arranged in a solid, trabecular or glandular architecture. The tumor’s cells are
immunohistochemically positive for a variety of keratin antibodies and most of them are also
positive for neuroendocrine markers. Surgical excision is the treatment of choice. Local recurrence
following complete excision is quite uncommon and metastases are rare.
Conclusions: Our study and the review of the literature showed adenomas and carcinoid tumors of
the middle ear to be essentially indistinguishable benign tumors with metastatic potential. Based on
the presence or absence of immunohistochemical markers and metastasis, we have classified these
lesions into three types. Complete surgical treatment is recommended with an indefinite follow-up
for possible recurrence.
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Middle ear glandular neoplasms are seldomly the source
of a middle ear mass. Hyams [1] was the first to describe a
series of these tumors in 1976. He designated these tumors
as middle ear adenomas (MEA). In 1980, Murphy et al [2]
described a similar, if not identical, tumor and designated
it a carcinoid tumor because of the ultrastructural evidence
of a neuroendocrine differentiation.
Middle ear glandular neoplasms can present both a
neuroendocrine and an epithelial differentiation. This has
led some early authors to maintain that neuroendocrine
(carcinoid)tumorsandmiddleearadenomasweredifferent
tumors [3]. However, most authorities currently think that
there is a single primary low-grade glandular neoplasm of
the middle ear. They are describing carcinoid tumors of the
middle ear identical to the tumors reported as middle ear
adenomas. This has led most authorities to conclude that a
middle ear adenoma, or the variant neuroendocrine
adenoma, was a preferred nomenclature as opposed to
that of a carcinoid tumor since these terms imply a benign
behavior,whichisconsistentwiththe vastmajorityof cases.
In this paper, we present a new case of a middle ear
adenoma / carcinoid tumor. Our objective is to review all
cases described in the literature in order to identify the
clinical features, the gross pathology, the histopathology,
the immunohistochemistry, to discuss the differential
diagnosis, the treatment, the rate of recurrence, the follow-
up, the incidence of metastasis, the prognosis and to
present a new classification of middle ear glandular
neoplasm.
Materials and Methods
We performed a MEDLINE database search for MEA-
related articles published between 1950 and March 2008.
The electronic search was conducted with the keywords
“carcinoid”, “middle ear adenoma”, “middle ear mass”,
“middle ear tumor”, “ear adenoma”, “tympanic mass”,
“temporal bone tumor”, “neuroendocrine”, and “neu-
roendocrine immunohistochemistry”. The results yielded
74 relevant studies, in which 93 patient records were
transcribed. In addition, we adjoin our case to this series.
The information from the reports was analyzed to
characterize the clinical aspects, the radiologic findings,
the histopathology and immunohistochemistry, the treat-
ment, the rate of recurrence, the follow-up, and the
incidence of metastasis related this disease.
Case Presentation
In January of 2006, a 32-year old man presented at our
otolaryngology department for a second opinion regard-
ing a seven-year history of right aural fullness and mild
hearing loss. Five years prior to this consult, he had been
examined by an otorhinolaryngologist for a right-sided
otalgia associated with a right facial paralysis. He had been
given oral amoxicillin and steroids for a probable middle
ear otitis complicated with a facial paralysis. A few months
after this episode, an antero-inferior myringotomy was
performed for a presumed middle ear effusion and revealed
neither liquid, nor mass. He had never noticed any
discharge, vertigo, tinnitus, visual symptoms or headaches,
as well as any other significant past or present disease.
The otoscopy showed the presence of a posterosuperior
retrotympanic mass with normal tympanic membrane.
The hearing test revealed a right mixed hearing loss.
A computed tomography (CT) scan of the temporal bone
revealed opacity in the superior part of the middle ear
extending into the mastoid cavity (Figure 1). There was
neither bone erosion, nor ossicular destruction and it was
compatible with a chronic otomastoiditis.
In March 2006, he underwent a right postauricular canal
wall-up mastoidectomy and an extended facial recess
approach procedure. A multilobulated, polypoid, fibrotic,
grey tumor was observed filling the middle ear cavity. The
mass was located in the mesotympanum, epitympanum
and hypotympanum components. There was a prolonga-
tion into the antrum, the mastoid, and the Eustachian tube
without any involvement of the facial nerve or evidence of
bone erosion. Even if the ossicles were embedded in the
tumor, there was no ossicular chain erosion, but the
malleus was fractured, the incus and the stapes were
dislocated. The malleus and incus were removed and a
piece of fascia was placed on the oval window to avoid a
Figure 1.
Axial (A) and coronal (B) views of a mastoid computerized
tomography (CT) scan showing a right mastoid and middle
ear opacity. The tympanic membrane is pressed laterally
by the mass.
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not conclusive. A total macroscopic excision of the lesion
was performed; a second look procedure for ossicular
chain reconstruction was to be performed five months
later. There were no major postoperative complications.
The hearing test showed a right severe sensorineural
hearing loss, which was improved by a hearing aid.
Histologic examination of the excised tumor showed an
epithelial neoplasm with a predominantly glandular
architecture embedded in fibrous tissue. The tumor was
composed of cuboidal cells with uniform nuclei and no
identifiable mitotic activity or necrosis (Figure 2). Focally,
the tumor cells had a well-developed plasmacytoid mor-
phology (Figure 3). Single cells were also seen infiltrating
into the fibrous stroma. An immunohistochemical evalua-
tion showed strong positivity for neuron specific enolase
(NSE) and synaptophysin and weak positivity for chromo-
granin (Figure 4). The tumor was suspected of having the
typicalmorphologyandimmunophenotypeofamiddleear
adenoma/carcinoid. The patient was clinically monitored
for two years through the T1 and T2-weighted magnetic
resonance imaging (MRI) images of the temporal bones
withtheadministrationofaparamagneticcontrastmaterial.
He is currently disease free (Figure 5).
Results
We uncovered 74 relevant studies. Ninety-four cases of
middle ear adenoma/carcinoid tumor of the middle ear
have been published; including our own afore-described
case. We identified 75 patients with a diagnosis of middle
ear carcinoid tumor and 19 patients with a diagnosis of
middle ear adenoma. The patient’s age in this series ranged
from 16 to 77 years with a mean age of 44.6 years.
The incidence of right versus left involvement was equal.
Therewere41womenand53menyieldingafemaletomale
ratio of 1:1.3.
Clinical Presentation
Hearing loss (HL) was the most common pre-
senting symptom (86.3%). The majority had conductive
HL (Table I); four patients had sensorineural hearing loss
Figure 2.
Middle ear adenoma. Tumor composed of small glands lined
by a single layer of uniform cuboidal cells with an intraluminal
eosinophilic secretion. No mitotic activity or necrosis (original
magnification 400X).
Figure 3.
Middle ear adenoma. Minor foci of tumor composed of sheets
of loosely cohesive cells with moderate to abundant
eosinophilic cytoplasm and eccentrically placed nuclei
(plasmacytoid morphology) (original magnification 200X).
Figure 4.
Middle ear adenoma. Immunohistochemical stains for
synaptophysin (A) and chromogranin (B) show strong
positivity within tumor cells.
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facialfunctionweakness;sevenhadresolutionaftertreatment
whiletwoofthemhaddirectinvasionrequiringsacrificingthe
nerve.Thedurationofthesymptomsvariesfromsevendaysto
twenty years, with an average of 38 months.
Radiographic Studies
A CT scan of the temporal bones was performed in 68% of
patients and demonstrated a soft tissue mass in the middle
ear. The ossicles were embedded by the tumor without
bone or ossicular erosion in all the cases except for one
patient (Table I). An evaluation including a CT of the neck,
chest, and abdomen was done in two patients and did not
reveal a metastatic disease. A few cases (11%) have had
plain mastoid x-rays or conventional tomography (4%)
and revealed, in most of them, opacity of the mastoid air
cells. In 5% of cases, no radiological investigation was
completed. In three cases, a postoperative CT scan of the
temporal bones was completed, the delays were not
specified. In our case presented here, an MRI of the
temporal bone was completed on the postoperative first
and second year.
Intraoperative Findings
Grossly, the tumors present different appearances. The
aspect was clearly described in 48 patients (Table I). It was
gray-white in 35%, fibrotic, polypoid or multilobulated in
15%, cholesterol-like or fatty in 9%, yellowish jelly-like in
25%, reddish non vascular and non pulsatile in 14%,
cholesteatoma-like in 2%, and of unspecified color for the
remaining patients. The epicenter of the tumor was located
in themiddle ear withan extension to the mesotympanum
in 65% of cases, to the hypotympanum in 53%, and to the
epitympanum in 49%. The aditus ad antrum was involved
in seven patients, the mastoid in ten patients, and the
Eustachian tube in four patients. In 38 patients, there was
no precise description of the tumor’s location. The tumors
may be relatively well-circumscribed, but not encapsu-
lated; they peel off the bony walls of the middle ear, but
may entrap and destroy the ossicles. Ossicular involve-
ment occurred in 70% of cases, but only eight cases had
ossicular erosion. The majority of reports indicate that
ossicles were removed with the tumor excision. Facial
paresis was identified in nine cases and the nerve was
frankly invaded in only two cases.
Histopathology
In this series, 75 cases were diagnosed as carcinoid tumor
because of their positivity to neuroendocrine markers on
immunohistochemistry (Table II). The 19 remaining cases
Figure 5.
Axial (A) and coronal (B) T2-weighted magnetic resonance
imaging (MRI) scan one-year post-operative excision showing
no sign of recurrence.
Table I. Clinincal, radiographic, intraoperative findings and follow up of middle ear adenoma (19 cases) and carcinoid tumor (75 cases)
reported in the literature including our case. External auditory canal (EAC)
Clinical
presentation
Radiographic presentation Intraoperative findings
Tumor localisation / Middle
ear with extension to:
Follow up
Hearing loss 86.3%
Aural fullness 33%
Tinnitus 27.6%
Otalgia 15%
Otorhhea 11.4%
Facial weakness 11%
Mean duration of
symptoms: 38
months
CT
scan
(68%)
Mastoid 18% Mesotympanum 65%
Hypotympanum 53%
Epitympanum 49%
Aditus ad antrum 15%
Mastoid 15%
Eustachian tube 7%
No precise description 20%
Mean : 53 months [2-396]
EAC 3%
Eustachian tube 2% Recurrence rate: 12.7%
Fallopian canal 2% Time for recurrence: 108 months
[13-516] Jugular foramen 2%
Tegmen antri lysis < 1% Local recurrence (N=8): 67%
MRI
(13%)
Low to moderate signal T1 Local + regional recurrence (N=4): 33%
High signal T2 Disease free from last treatment:
26 months [5-60] Enhancement Contrast
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pathology and histopathology. Neuroendocrine markers
were done just in one out of the nineteen cases and results
were negative. No molecular genetic studies have been
performed on middle ear adenoma.
Treatment
All patients were primarily treated with surgery. Transcanal
tympanotomy (TM) or tympano-mastoidectomy
approaches were used. Seventeen patients underwent an
initial biopsy followed by a more definitive procedure
such as canal wall up (CWU) mastoidectomy, canal wall
down (CWD) mastoidectomy, or radical mastoidectomy
(RM). A secondary ossicular reconstructive procedure was
only documented in our reported case. The definitive
surgical treatment was through a transcanal TM in 46% of
patients, CWU mastoidectomy in 21% of patients, CWD
mastoidectomy in 16%, and RM in 22% of patients. Four
patients underwent a subtotal petrosectomy, three patients
simply underwent a biopsy, one was treated by the
excision of the EAC mass, and eight had unspecified
surgery combined with postoperative radiation therapy;
a dose ranging from 45 to 60 Gray. Chemotherapy was not
prescribed in any other cases.
Recurrence and Metastasis
Sixty-one patients were disease free at their last follow-up,
21 patients had an unspecified follow-up while twelve
(12.7%) patients developed a localized recurrence of the
disease (Table I). Only one case out of these twelve
patients had MEA. No immunohistochemistry test was
done. The average interval from initial treatment to the
first recurrence was nine years from a range of 13 months
to 43 years. In all recurrences, the initial excision was
conservative, leaving the ossicular chain intact.
Tympanotomy was associated with a local recurrence
rate of 14%, whereas radical mastoidectomy was asso-
ciated with a local recurrence rate of 9%.
Follow-up
The disease-free interval after definitive surgery was
available for 73 of the patients. This interval ranged from
two months to 33 years with an average of 53 months. The
follow-up for the patients treated with radiotherapy was
not indicated. The interval between initial surgery and first
recurrence was available for eleven patients and ranged
from 16 to 396 months with an average of 52 months. The
duration of the follow-up after treatment for a recurrent or
a metastatic disease was available for nine of the patients,
ranging from five months to five years with an average of
26 months.
Discussion
Middle ear adenomas are unusual neoplasms with
epithelial and neuroendocrine differentiations. They are
composed of two types of cells; exocrine and neuroendo-
crine in which neuroendocrine granules and sometimes
neuropeptides (chromogranin, synaptophysin, serotonin,
and pancreatic polypeptide) are detected [4, 5].
Etiology
Carcinoid tumors of the lung are thought to originate from
enterochromaffin cells (Kulchitsky cells), which are
neuroendocrine normal cells present in the lung. How-
ever, epithelial cells with neuroendocrine characteristics
are not noted in the middle ear cavity. An undifferentiated
pluripotential endodermal stem cell may still be present
within the surface mucosa, giving rise to carcinoid
neoplasms similar to the Kulchitsky cell [6]. Hyams and
Michaels were the first to hypothesize that MEA originated
Table II. Immunohistochemical Data of Reported Cases per Years represented by percentage of positive cases
Immunohistochemistry 2008 – 2000
22 cases
1999 – 1990
30 cases
1989 – 1967
23 cases
Total of positive test
(2008 – 1967)
Chromogranin A 86% 53% 25% 44%
Neuron Specific Enolase (NSE) 59% 51% 29% 39%
MET secretory granule 4.5% 33% 58% 26%
Synaptophysin 50% 24% - 20%
Serotonin 5% 40% 25% 20%
Vimentin 14% 27% 21% 17%
Cytokeratin 14% 30% 12% 16%
Keratin 14% 20% 21% 15%
Pancreatic polypeptide (PP) - 30% 21% 15%
Grimelius 5% 20% 17% 12%
Glucagon - 17% 17% 10%
Epithelial Membrane Antigen (EMA) 18% - 17% 8%
Protein S-100 - 10% 12% 6%
Immunohistochemistry positive result less than 5% (are not reported in the table) of cases for the period from 1967 to 2008: Cytokeratin AE1 / AE3,
Cytokeratin cocktails, Cytokeratin KL 1, Cytokeratin CAM, Carcino Embryogenic Antigen (CEA), Periodic Acid-Schiff (PAS), Tissue polypeptide
antigen (TPA), Calcitonin, Lyzozyme, Leu-7, Cholecystokinin, Fontana-Masson, Protein gene product 9.5 (PGP), Stomatostatine, Vasoactive intestinal
polypeptide (VIP).
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lack of evidence for surface epithelial derivation leads to
the consideration of a stromal precursor [1]; the stroma of
the middle ear derived from the mesoderm and the neural
crest. The neural crest gives rise to parts of the ossicular
chain and the three primary paraganglia. Positive immu-
nohistochemical staining for neuroendocirne tissue, NSE,
chromogranin, and/or synaptophysin suggest that ade-
noma of the temporal bone originates from neuroecto-
derm. Epithelial and exocrine characteristics are not
normal features of these cells and it is plausible that a
neuroendocrine neoplasm of the middle ear may originate
from a neural crest-derived stem cell.
Clinical Presentation
The mean age being the forties and there was no gender
difference. Patients typically present with conductive hear-
ingloss, aural fullness, andtinnitus. Anexaminationusually
reveals a gray-white or fibrotic mass behind an intact
tympanic membrane. Facial palsies associated with middle
ear carcinoid have been reported in the literature. Krouse et
al. presented one patient with transient paresis [7] and
similar findings were described inthe report of Torske et al.,
who retrospectively analyzed 48 cases from the archives of
theArmedForcesInstituteofPathology[8].Innoneofthese
cases was the nerve infiltrated by the tumor. However, bone
dehiscences of the facial canal were described, which could
be related to either anatomic abnormalities or the tumor
itself. Even in normal ears, the rate of minor dehiscence of
the bony canal is rather high. In the report of Nikanne at al
[9] and in our case, the facial function returned to normal
before any surgical treatment. In these cases “clinically”
intact shell around the facial nerve makes every discussion
about the damaging mechanism difficult and speculative.
Friedmann et al. presented a patient who had a tumor
enveloping the facial canal, but without any invasion of the
nerve [3]. Ramsey et al reported a case with facial paresis
associated with invasion of the facial nerve and an
intraneural spread [10]. Knerer et al. reported another
patient who required facial nerve sacrifice because of tumor
involvement[11].Thecarcinoidtumorbelongstothegroup
of APUDomas (Amine Precursor Uptake and Decarboxyla-
tion) or endocrine cell tumors. Only Latif and al. reported a
carcinoid syndrome from a neuroendocrine tumor of the
middleear[12].Itistheonlyreportedcasewherethepatient
complained of diarrhea, abdominal cramps, skin flushing,
and bronchoconstiction. Clinical identification is usually
misinterpreted as cholesteatoma, chronic otitis media or
paraganglioma, schwannoma, hamartoma, squamous cell
carcinoma, rhabdomyosarcoma, and papillary
adenocarcinoma.
Radiology
Since the clinical features and otological findings are not
characteristic, one must rely on radiological findings. The
imaging characteristics of adenomatous middle ear tumors
have not been clearly defined because of their rarity.
However, the CT of the temporal bone is the key
procedure. It highlights a nonspecific opacity, well limited,
being able to extend to the whole of the tympanic cavity
and the mastoid and posing mainly the differential
diagnosis from a glomic tumor. The ossicles are generally
embedded in the mass without ossicular or bony erosion.
No characteristic differences between the benign and
malignant tumors are detectable on a CT [13]. On an
MRI, the tumors are isointense or generated a slightly
higher signal than white matter on T1-weighted images;
there is contrast enhancement. On T2-weighted images,
the tumors approximate the signal intensity of gray matter
[13]. Although the ossicles are visible as signal voids
within the tumor, bone erosion could not be assessed.
Indeed,an MRI does notprovide preoperative information
in addition to that generated by a CT, mainly due to the
small size of the tumors. In cases with extension to the
posterior cranial fossa or cerebellopontine angle, an MRI is
expected to provide additional help in the diagnosis and
in planning the resection. CT and MRI in the investigation
of a suspected middle ear tumor are recommended.
Intraoperative Findings
All patients presented with a unilateral disease. Most of the
lesions were excised in a piecemeal fashion and they peel
off the bony walls of the middle ear, but may entrap and
destroy the ossicles. The biological nature of the tumors
could not even be assessed intraoperatively. Facial
paralysis, bone lyses, or chronic otorrhea can exist in the
case of a malignant lesion. None of these symptoms is
specific. The surgeon should keep in mind the possibility
of a middle ear adenoma especially in the presence of a
fibrotic mass behind an intact tympanic membrane.
Pathological Findings
Microscopically, all tumors were unencapsulated and of
moderate cellularity. They were predominantly composed
of cuboidal-to-columnar cells with indistinct cytoplasmic
borders. The cytoplasm was eosinophilic and homoge-
nous to finely granular. The nuclei tended to be round to
oval with minimal pleiomorphism [14]. The chromatin
tended to display a “salt-and-pepper” pattern consistent
with a neuroendocrine origin. Architectural patterns
include glandular, trabecular, solid, and infiltrative. The
architecture varied between tumors and within the same
tumor.
Immunohistochemistry reveals that the tumor is typically
keratin-, vimentin-, pancreatic polypeptide-, and chromo-
granin-positive,withalessernumberoftumorsprovingtobe
neuron-specific-enolase (NSE), synaptophysin-, serotonin-
and S-100 protein-positive [15]. Immunohistochemical is
also positive with a variety of neuroendocrine-associated
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peptide [16]. We found that chromogranin, NSE, MET,
synaptophysin, and serotonin are positive in more than 20%
of cases and since 1967, are almost always performed. We
suggest that these markers should be tested in all MEA
suspected cases to rule out a carcinoid tumor.
Classification
An analogy between MEA and carcinoid has been
proposed. Torske and Thompson have suggested that
both are the same tumor [8]. On the other side Ramsey
concludes that a carcinoid tumor of the middle ear is the
appropriate term and should be considered as a distinct
entity from the MEA [10]. Middle ear carcinoid was
reported to have a metastatic potential, so it should be
considered as a low-grade malignancy [10, 17, 18]. Some
have suggested using neuroendocrine adenoma of the
middle ear as a more descriptive term [8, 19]. In the
nineteen cases of MEA reported here, immunohistochem-
istry was negative in only one case and it was not
performed or unspecified in the remaining cases. Based
on these different descriptions and on the presence or
absence of markers and metastases, we classified these
lesions into three types (Saliba’s classification of middle
ear glandular neoplasms) (Table III): the most common
one (type I) is the neuroendocrine adenoma of the middle
ear (NEAME) (76%) (positive immunohistochemistry,
negative metastasis) followed by (type II) the middle ear
adenoma (MEA) (20%) (negative immunohistochemistry,
negative metastasis), and the least common one (4%)
(type III) is the carcinoid tumor of the middle ear
(CTME) – positive immunohistochemistry, positive
metastasis and / or carcinoid syndrome - associated to a
metastasis most commonly found in theipsilateral parotid
gland. We propose this classification to discard ambiguity
in the diagnosis category, to clarify each group of middle
ear glandular neoplasm and for prognostic expectation.
Upon this classification, we recognize that only type I
tumor can develop metastasis and recurrence could be
related only to positive immunohistochemistry cases. In
addition, immunohistochemistry was not done in 16 out
of 19 MEA reported cases, which suggests that the
percentage of MEA probably represents less than 20% of
the cases. Pellini et al presented the only case of middle ear
free, temporal bone carcinoid metastasis to the cervical
lymph nodes [20].
Treatment
Complete surgical removal of the neoplasm including the
encased ossicles should be the preferred treatment. When
the ossicular chain is involved, but not removed, the
recurrence of the lesion is more likely to occur. The surgery
should be determined on the basis of the clinical and
radiological findings. The incidence of recurrence is higher
with transcanal tympanotomy (14%) than with a radical
mastoidectomy (9%). This is insufficient evidence to
suggest superiority of one procedure over another. CWU
mastoidectomy with an extended facial recess approach
could be an option. In some cases, patients were treated
with repeated debulking-excision procedures to preserve
the ossicular chain and thus, retain their hearing.
Discouraged by surgeons, this technique would require a
continued long term clinical follow-up and patient
compliance. In order to prevent recurrence, the treatment
of choice is total exploration and surgical excision with
removal of the ossicular chain [21].
Radiation, chemotherapy and somatostatin analogues
have been used in the treatment of gastrointestinal and
pulmonary carcinoid tumors, but no data exists for the
treatment of middle ear carcinoid. Radiation therapy is not
required for these tumors [7]. In fact, secondary malignant
transformation is a possible outcome as we have seen with
a case of metastatic spread [17].
Recurrence
In all recurrences, the initial excision was conservative,
leaving the ossicular chain intact and the immunohisto-
chemistry, when done, was positive. We noted that all the
patients who underwent biopsy followed by definitive
surgery had no recurrent disease. Regional metastasis
occurredinfourpatients.Theyshouldbemanagedsurgically
withaparotidectomyoraneckdissection.Nikanneetalused
octreotide scanning in one case in the management of a
carcinoid tumor [9]. In another case, a recurrence of middle
ear carcinoid was detected by Indium-111(In-111) pente-
treotide scintigraphy; its usefulness for the detection of a
carcinoid tumor is well known, but has rarely been
documented for the detection and follow-up [22].
Follow-up
The disease-free interval after definitive surgery averaged
53 months. All of the authors recommend a long-term
clinical follow-up, but most of them do not specifically
recommend a radiological control. When an ossicular
chain reconstruction is performed and the usage of
Table III. Saliba’s classification of middle ear glandular neoplasms
based on the presence or absence of markers and metastases.
(NEAME: neuroendocrine adenoma of the middle ear; MEA:
middle ear adenoma; CTME: carcinoid tumor of the middle ear;
(+): positive; (−): negative)
Type Description Characteristics Percentage
I NEAME Immunohistochemistry (+)
Metastasis (−)
76%
II MEA Immunohistochemistry (−)
Metastasis (−)
20%
III CTME Immunohistochemistry (+)
Metastasis (+)
and / or Carcinoid syndrome (+)
4%
Page 7 of 8
(page number not for citation purposes)
Cases Journal 2009, 2:6508 http://casesjournal.com/casesjournal/article/view/2/3/6508cartilage for tympanoplasty middle ear examination
becomes impossible, we recommend that either a CT
scan or an enhanced MRI be completed.
Conclusion
Middle ear glandular neoplasms are uncommon well-
documented neoplasms of the middle ear. We suggest a
prognostic helpful classification based on the presence or
absence of markers and metastasis; type I (NEAME), type II
(MEA), and type III (CTME). Despite considerable debate
over the similarities and differences between these tumors,
we believe they are clinically identical, but immunohisto-
chemical results make the difference. This review demon-
strates a 12.7% recurrence rate after excision. Surgical
management with ossicular chain removal is the recom-
mended treatment to ensure a complete excision. Long-
term follow-up is important because of the late recurrences
and metastases.
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